HomeCompareNPKLY vs ABBV

NPKLY vs ABBV: Dividend Comparison 2026

NPKLY yields 4.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.6K in total portfolio value
10 years
NPKLY
NPKLY
● Live price
4.44%
Share price
$21.00
Annual div
$0.93
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.7K
Annual income
$590.66
Full NPKLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NPKLY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPKLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPKLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPKLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPKLY
Annual income on $10K today (after 15% tax)
$377.64/yr
After 10yr DRIP, annual income (after tax)
$502.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,553.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPKLY + ABBV for your $10,000?

NPKLY: 50%ABBV: 50%
100% ABBV50/50100% NPKLY
Portfolio after 10yr
$64.5K
Annual income
$12,681.21/yr
Blended yield
19.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NPKLY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPKLY buys
0
ABBV buys
0
No recent congressional trades found for NPKLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPKLYABBV
Forward yield4.44%3.06%
Annual dividend / share$0.93$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$26.7K$102.3K
Annual income after 10y$590.66$24,771.77
Total dividends collected$5.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPKLY vs ABBV ($10,000, DRIP)

YearNPKLY PortfolioNPKLY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,144$444.29$11,550$430.00$406.00ABBV
2$12,387$462.73$13,472$627.96$1.1KABBV
3$13,735$480.69$15,906$926.08$2.2KABBV
4$15,194$498.12$19,071$1,382.55$3.9KABBV
5$16,773$515.01$23,302$2,095.81$6.5KABBV
6$18,479$531.32$29,150$3,237.93$10.7KABBV
7$20,319$547.05$37,536$5,121.41$17.2KABBV
8$22,304$562.19$50,079$8,338.38$27.8KABBV
9$24,442$576.72$69,753$14,065.80$45.3KABBV
10$26,743$590.66$102,337$24,771.77$75.6KABBV

NPKLY vs ABBV: Complete Analysis 2026

NPKLYStock

Nampak Limited manufactures and sells metal, plastic, and paper packaging products in South Africa and rest of Africa. The company offers HDPE and PET bottles and jars, plastic closures, tubes, and crates and drums for the fruit juice, dairy, carbonated soft drink, water, alcoholic beverage, bakery, agriculture, chemical, petroleum, personal care, and household markets. It also provides aluminum beverage cans and ends for the alcoholic, carbonated soft drink, fruit juice, energy drink, vegetable juice, and ice tea markets; tinplate food cans for the canned food market; and aluminum and tinplate cans, including aerosols, monoblocs, and paint and shoe polish cans to the personal care, household goods, and industrial markets, as well as crowns for the beverage market. In addition, the company offers beverage cartons for milk, fruit juice, water, and traditional beer; self-opening paper bags for the flour and sugar markets; and corrugated cases/boxes for the tobacco, poultry, and food and general commercial markets, as well as labels and folding cartons for the tobacco, food and beverage markets. Nampak Limited is headquartered in Sandton, South Africa.

Full NPKLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NPKLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPKLY vs SCHDNPKLY vs JEPINPKLY vs ONPKLY vs KONPKLY vs MAINNPKLY vs JNJNPKLY vs MRKNPKLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.